[go: up one dir, main page]

WO2001018030A3 - Small peptides having potent anti-angiogenic activity - Google Patents

Small peptides having potent anti-angiogenic activity Download PDF

Info

Publication number
WO2001018030A3
WO2001018030A3 PCT/SG2000/000131 SG0000131W WO0118030A3 WO 2001018030 A3 WO2001018030 A3 WO 2001018030A3 SG 0000131 W SG0000131 W SG 0000131W WO 0118030 A3 WO0118030 A3 WO 0118030A3
Authority
WO
WIPO (PCT)
Prior art keywords
potent anti
angiogenic activity
small peptides
peptides
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SG2000/000131
Other languages
French (fr)
Other versions
WO2001018030A2 (en
Inventor
Rowen Ge
R Manjunatha Kini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National University of Singapore
Original Assignee
National University of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University of Singapore filed Critical National University of Singapore
Publication of WO2001018030A2 publication Critical patent/WO2001018030A2/en
Publication of WO2001018030A3 publication Critical patent/WO2001018030A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides peptides having potent anti-angiogenic activity. The peptides can be administered as pharmaceutical compositions for prevention or treatment of undesired angiogenesis, for instance for prevention of tumor metastasis or inhibition of primary tumor growth.
PCT/SG2000/000131 1999-09-03 2000-09-01 Small peptides having potent anti-angiogenic activity Ceased WO2001018030A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG9904310-1 1999-09-03
SG9904310A SG87828A1 (en) 1999-09-03 1999-09-03 Small peptides having potent anti-angiogenic activity

Publications (2)

Publication Number Publication Date
WO2001018030A2 WO2001018030A2 (en) 2001-03-15
WO2001018030A3 true WO2001018030A3 (en) 2001-09-27

Family

ID=20430423

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SG2000/000131 Ceased WO2001018030A2 (en) 1999-09-03 2000-09-01 Small peptides having potent anti-angiogenic activity

Country Status (2)

Country Link
SG (1) SG87828A1 (en)
WO (1) WO2001018030A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20060625A1 (en) * 2006-03-31 2007-10-01 Istituto Naz Per La Ricerca ANTIANGIOGENIC PEPTIDE AND ITS THERAPEUTIC USES
WO2014037332A1 (en) * 2012-09-04 2014-03-13 Università Degli Studi Di Torino Inhibitors of alpha6 integrin/e-cadherin complex and their therapeutic and diagnostic use in cancer
WO2019043649A2 (en) * 2017-08-31 2019-03-07 Singapore Health Services Pte Ltd Angio-3 for treatment of retinal angiogenic diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997015666A1 (en) * 1995-10-23 1997-05-01 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
WO1997041824A2 (en) * 1996-05-03 1997-11-13 Abbott Laboratories Antiangiogenic peptides derived from plasminogen
WO2000026368A2 (en) * 1998-10-30 2000-05-11 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997015666A1 (en) * 1995-10-23 1997-05-01 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
WO1997041824A2 (en) * 1996-05-03 1997-11-13 Abbott Laboratories Antiangiogenic peptides derived from plasminogen
US6057122A (en) * 1996-05-03 2000-05-02 Abbott Laboratories Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis
WO2000026368A2 (en) * 1998-10-30 2000-05-11 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions

Also Published As

Publication number Publication date
WO2001018030A2 (en) 2001-03-15
SG87828A1 (en) 2002-04-16

Similar Documents

Publication Publication Date Title
WO2002080890A3 (en) A jasmonate pharmaceutical composition for treatment of cancer
WO2002070438A3 (en) Compositions for delivering bisphosphonates
WO2002048147A3 (en) Pyrazolopyridines
WO2001098236A3 (en) 7-phenyl-substituted tetracycline compounds
IL162214A0 (en) Pyridine derivatives and pharmaceutical compositions containing the same
MXPA03004832A (en) Compounds and their uses.
MY134136A (en) Novel compounds comprising jak3 kinase inhibitors
ZA200110504B (en) Dietary or pharmaceutical compositions for use for the prevention or treatment of hyperoxaluria.
WO2002064083A3 (en) Synthesis of 3-amino-thalidomide and its enantiomers
WO2001081310A8 (en) 1-aroyl-piperidinyl benzamidines
IL143921A (en) Compositions for the treatment and prevention of tumor-related disorders, for inhibiting tumor growth and for inhibiting tumor metastasis
WO2001056552A3 (en) Farnesyl protein transferase inhibitors for treating breast cancer
AU2001271987A1 (en) Non-genotoxic metalloporphyrins as synthetic catalytic scavengers of reactive oxygen species
WO2003041653A3 (en) Cytotoxic agents
WO1998008505A8 (en) Pharmaceutical compounds
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
WO2003037863A3 (en) Substituted indoles, method for production and use thereof for the inhibition of pain
WO2003051838A3 (en) Protein kinase inhibitors
WO2001046455A3 (en) Survivin promotion of angiogenesis
IL157065A0 (en) 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
WO2003037912A3 (en) Tri-, tetra-, and penta-peptides having antiangiogenic activity
WO2003066022A3 (en) Stable pharmaceutical composition useful for treating gastrointestinal disorders
WO2002047604A3 (en) Novel use of chalcone class compounds for inhibiting tumoral mass vascularization
WO2001018030A3 (en) Small peptides having potent anti-angiogenic activity
MXPA04000805A (en) Peptides having antiangiogenic activity.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CN JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CN JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP